Sign In
Buy AXSM
$212.85
+0.680 (+0.320%)
At Close: Aug 05, 2026
3 Stocks Savvy Investors Are Buying Hand Over Fist
09:27am, Thursday, 06'th Oct 2022 The Motley Fool
These high-flying stocks are defying the bear market.
Axsome Therapeutics: Clear Path Ahead For AXS07
05:15pm, Wednesday, 05'th Oct 2022
Despite the recent downtrend in its trading, Axsome Therapeutics, Inc.'s fundamentals are stronger than ever. Asides from the Sunosi acquisition, the company recently gained Auvelity approval to treat
3 Healthcare Stocks That Could Make You Richer
10:30am, Wednesday, 05'th Oct 2022 The Motley Fool
It's all about much-needed products.
3 Healthcare Stocks That Could Make You Richer
06:30am, Wednesday, 05'th Oct 2022
It's all about much-needed products.
Axsome Therapeutics (AXSM) Gains But Lags Market: What You Should Know
10:00pm, Monday, 03'rd Oct 2022 Zacks Investment Research
Axsome Therapeutics (AXSM) closed at $45.33 in the latest trading session, marking a +1.59% move from the prior day.
Axsome Therapeutics Announces Sunosi® (Solriamfetol) Meets Primary Endpoint Demonstrating Improvement in Cognitive Function in the SHARP Trial in Cognitively Impaired Patients with Excessive Daytime Sleepiness Associated with Obstructive Sleep Apnea
10:30am, Monday, 03'rd Oct 2022 GlobeNewswire Inc.
Statistically significant improvement in cognitive function, as measured by the DSST RBANS compared to placebo (p=0.009, primary endpoint)
Axsome Therapeutics (AXSM) Gains As Market Dips: What You Should Know
10:15pm, Friday, 30'th Sep 2022 Zacks Investment Research
Axsome Therapeutics (AXSM) closed the most recent trading day at $44.62, moving +1.06% from the previous trading session.
8 Analysts Have This to Say About Axsome Therapeutics
02:37pm, Friday, 30'th Sep 2022 Benzinga
Analysts have provided the following ratings for Axsome Therapeutics (NASDAQ:AXSM) within the last quarter:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
3
1
4
0
Axsome Therapeutics Announces Plans to Resubmit AXS-07 NDA Based on Successful FDA Type A Meeting
11:28am, Thursday, 29'th Sep 2022 GlobeNewswire Inc.
NEW YORK, Sept. 29, 2022 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous sys
2 No-Brainer Biotech Stocks to Buy Right Now
01:53pm, Monday, 26'th Sep 2022 The Motley Fool
If one can bear the risk with these stocks, the rewards can be extraordinary.
3 Monster Stocks in the Making
10:14am, Saturday, 24'th Sep 2022 The Motley Fool
These companies are small now. But they have massive long-term growth prospects.
3 Monster Stocks in the Making
06:14am, Saturday, 24'th Sep 2022
These companies are small now. But they have massive long-term growth prospects.
If You Invested $10,000 in Axsome Therapeutics 5 Years Ago, This Is How Much You Would Have Today
10:50am, Friday, 23'rd Sep 2022 The Motley Fool
Is it too late to invest in this biotech?
2 Reasons to Buy Axsome Therapeutics, and 1 Reason to Sell
10:30am, Thursday, 22'nd Sep 2022 The Motley Fool
Axsome just won approval of a potential blockbuster.
Axsome Therapeutics to Present at the Ladenburg Thalmann Healthcare Conference
07:00am, Wednesday, 21'st Sep 2022
NEW YORK, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous syste
